Cite
APA Citation
Lei, T., Xu, T., Zhang, N., Zou, X., Kong, Z., Wei, C., & Wang, Z. (2023). anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis. Pharmacological research, 188, . http://access.bl.uk/ark:/81055/vdc_100177575112.0x00001e